There are virtually no data concerning the risk of adverse events (AEs) following lower gastrointestinal (LGI) endoscopic ultrasound (EUS).
Dr Michael Levy and colleagues from Minnesota, USA determined the incidence and factors associated with adverse events following lower gastrointestinal EUS fine needle aspiration (FNA).
The research team conducted a prospective cohort study at a tertiary referral center.
The researchers reported that 563 patients underwent LGI EUS FNA between 2004 and 2012.
The team analyzed the 502 patients who had complete follow-up.
|Adverse events developed in 21% of patients |
|American Journal of Gastroenterology|
Adverse events severity was graded (1–5) utilizing Common Terminology Criteria or Visual Analog Scale.
The team assessed adverse events during the procedures, in clinical follow-up, during phone interviews conducted at 7–14 days, and final clinical and/or phone interviews at 2–4 months.
The researchers found that adverse events developed in 21% of patients and were classified as grade 1, 2, 3, or 4 in 7%, 8%, 5%, and 1% of patients, respectively.
The team noted that bleeding and pain were the commonest adverse events.
No deaths occurred.
The research team found that adverse events were associated with prior pain, FNA from a site other than a lymph node or gut wall, and malignant FNA cytology, serious adverse events were associated with prior pain, and FNA from a site other than a LN or gut wall.
Dr Levy's team concludes, "Lower gastrointestinal EUS FNA is associated with a high rate of serious grades 3–4 adverse events."
"This may reflect the total number of associated interventions and the frequency of underlying pathology and symptoms."